Structuring Protein-Specific Life Science Partnerships
Law360 (February 2, 2021, 6:21 PM EST) -- During the ongoing COVID-19 pandemic, many of us have undoubtedly become familiar with SARS-CoV-2's infamous spike protein. The well-known mRNA vaccines for the virus are designed to teach our cells how to make a harmless piece of the spike protein in order to elicit the creation of certain antibodies; those antibodies are what will protect us in the event that the real virus enters our bodies.
While the rapid discovery and development of such mRNA vaccines are certainly remarkable, the focus on particular proteins in the context of drug discovery and development is common.
Indeed, such efforts frequently focus on particular...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!